Seeking AlphaCodex · 实盘不做把握 5/10
北京时间·🕒 发布 04:27:42时区推断·⟳ 抓取 04:27:53·⚡ 决策 08-04 11:07:59 +6h40m·84.4 天前
Palantir、CRISPR Therapeutics和Diamondback盘后业绩摘要
Palantir Q2 Non-GAAP EPS为0.41美元、超预期0.06美元，收入19.4亿美元、同比+94%、超预期1.30亿美元，但同一财报催化已多次处理。
📄 原文Seeking Alpha↗ 原文
Stocks to watch on Monday after hours: PLTR, CRSP, and FANG
U.S. stocks finished higher on Monday, with all three major indexes posting solid gains as traders looked ahead to more…
不做 Palantir（PLTR.US）
同一Palantir二季度业绩超预期并上调指引催化已多次处理，且盘后已快速重定价，不重复做。
不做 CRISPR Therapeutics（CRSP.US）
收入仅1018万美元，虽同比高增且亏损低于预期，但商业化量级不足，不能单靠财报摘要追多。
不做 Diamondback Energy（FANG.US）
EPS和收入beat属常规财报正面，未见新指引或资产层面催化，油气大盘股短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
关键理由
- Palantir Q2 Non-GAAP EPS为0.41美元、超预期0.06美元，收入19.4亿美元、同比+94%、超预期1.30亿美元，但同一财报催化已多次处理。
- CRISPR Therapeutics亏损小于预期且收入1018万美元，但收入基数很小，不足以单独形成商业化重定价。
- Diamondback Energy EPS为6.48美元、超预期0.50美元，收入55.6亿美元、超预期6.10亿美元，但属于常规油气财报beat，缺少新指引或结构性增量。
主要风险
- Palantir盘后已经快速重定价且已命中多条同一财报处理记录；CRSP和FANG只是同一篇盘后观察清单中的财报摘要。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
KB未提供改变方向的新反证；但去重和盘后已重定价使当前清单转述不再有新edge。
检索:Palantir Q2 2026 earnings revenue guidance AIP commercial government consensus
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,152 字
U.S. stocks finished higher on Monday, with all three major indexes posting solid gains as traders looked ahead to more earnings reports and key labor-market releases later in the week.
The Dow Jones Industrial Average (DJI) advanced +1%, the S&P 500 (SP500) climbed +1.3%, and the Nasdaq Composite (COMP:IND) jumped +2%.
Now, here are the three stocks to watch on Monday after hours:
Shares of Palantir (PLTR) surged +7.5% after hours after posting Q2 Non-GAAP EPS of $0.41, beating estimates by $0.06. At the same time, the company provided revenue that came in at $1.94B (+94% Y/Y), crushing consensus by $130M.
CRISPR Therapeutics (CRSP) climbed +2.3% after the bell after reporting a narrower-than-expected Q2 loss, with GAAP EPS of -$0.94 beating estimates by $0.23. Revenue jumped to $10.18M, surging more than 1,000% year-over-year and topping consensus by $2.75M.
Diamondback Energy (FANG) is also in focus in post-market trading after the oil and gas company reported strong second-quarter results. Non-GAAP EPS came in at $6.48, beating estimates by $0.50, while revenue reached $5.56B, up 51% year-over-year and $610M ahead of expectations.
The Dow Jones Industrial Average (DJI) advanced +1%, the S&P 500 (SP500) climbed +1.3%, and the Nasdaq Composite (COMP:IND) jumped +2%.
Now, here are the three stocks to watch on Monday after hours:
Shares of Palantir (PLTR) surged +7.5% after hours after posting Q2 Non-GAAP EPS of $0.41, beating estimates by $0.06. At the same time, the company provided revenue that came in at $1.94B (+94% Y/Y), crushing consensus by $130M.
CRISPR Therapeutics (CRSP) climbed +2.3% after the bell after reporting a narrower-than-expected Q2 loss, with GAAP EPS of -$0.94 beating estimates by $0.23. Revenue jumped to $10.18M, surging more than 1,000% year-over-year and topping consensus by $2.75M.
Diamondback Energy (FANG) is also in focus in post-market trading after the oil and gas company reported strong second-quarter results. Non-GAAP EPS came in at $6.48, beating estimates by $0.50, while revenue reached $5.56B, up 51% year-over-year and $610M ahead of expectations.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。